Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape
Australian & New Zealand Journal of Psychiatry December 17, 2025 Megan Dutton, Paul Schwenn, Jules S Mitchell et al. 1 citation
Australia’s reclassification of psilocybin as a Schedule 8 substance for treatment-resistant depression represents a significant shift in psychiatric policy. While this regulatory change positions Australia as a global leader in psychedelic medicine, its implementation has revealed substantial challenges. This article critically examines the regulatory, ethical and operational complexities...